Victoria Argentova

Victoria Argentova

Auto-generated profile, based on publicly available information

Victoria Argentova

Moscow State University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Biotechnology
Verified
Journal Article
Closed access
LPLucia Pažitná
Lucia Pažitná
MNMarek Nemčovič
Marek Nemčovič
ZPZuzana Pakanová
Zuzana Pakanová
PBPeter Baráth
Peter Baráth
TATeimur Aliev
Teimur Aliev
JKJaroslav Katrlík
Jaroslav Katrlík

22 February 2023 in Journal of Genetic Engineering and Biotechnology
Verified
Journal Article
Open access
PDF file
VTV. A. Toporova
V. A. Toporova
VAV. V. Argentova
V. V. Argentova
TAT. K. Aliev
T. K. Aliev
APA. A. Panina
A. A. Panina
DDD. A. Dolgikh
D. A. Dolgikh
MKM. P. Kirpichnikov
M. P. Kirpichnikov
The biopharmaceutical industry is significantly growing worldwide, and the Chinese hamster ovary (CHO) cells are used as a main expression host for the production of recombinant monoclonal antibodies. Various metabolic engineering approaches have been investigated to generate cell lines with improved metabolic characteristics for increasing longevity and mAb production. A novel cell culture method based on the 2-stage selection makes it possible to develop a stable cell line with high-quality mAb production. We have constructed several design options of mammalian expression vectors for the high production of recombinant human IgG antibodies. Versions for bipromoter and bicistronic expression plasmids different in promoter orientation and cistron arrangements were generated. The aim of the work presented here was to assess a high-throughput mAb production system that integrates the advantages of high-efficiency cloning and stable cell clones to stage strategy selection reducing the time and effort required to express therapeutic monoclonal mAbs. Development of a stable cell line using bicistronic construct with EMCV IRES-long link gave an advantage in high mAb expression and long-term stability. Two-stage selection strategies allowed the elimination of low-producer clones by using metabolic level intensity to estimate the IgG production in the early steps of selection. The practical application of the new method allows to reduce time and costs during stable cell line development.

1 April 2017 in Moscow University Biological Sciences Bulletin
Verified
Journal Article
Closed access
PDF file
VAV. V. Argentova
V. V. Argentova
TAT. K. Aliev
T. K. Aliev
VTV. A. Toporova
V. A. Toporova
VRV. S. Rybchenko
V. S. Rybchenko
DDD. A. Dolgikh
D. A. Dolgikh
MKMikhail P. Kirpichnikov
Mikhail P. Kirpichnikov
Production and application of therapeutic monoclonal antibodies are second only to vaccines in the world pharmaceutical market. The most common therapeutic antibodies are monoclonal antibodies (mAbs) of the IgG isotype that are produced in eukaryotic CHO cells. In recent years, there has been a considerable interest in developing treatment medications based on IgA antibodies, which can have a wide range of effector functions on human mucous membranes. To study the expression level of immunoglobulin A (IgA) in mammal cells, we designed a set of bipromoter (CMV and EF1α) vectors. The vectors contain gene fragments that encode the heavy chain variable domain (VH) and the light chain variable domain (VL) of the human monoclonal antibody FI6v3 against the hemagglutinin of influenza virus A. They also contain gene fragments that encode the light chain (kappa type) constant domain and the heavy chain constant domain of the human antibody IgA1. The expression vectors differed in the orientation of the promoters and the presence or absence of introns. Two variants of the full-length light and heavy chains were cloned into a eukaryotic expression vector in head-to-head and head-to-tail orientations. The resulting plasmids were transfected into CHO-DG44 and HEK-293T cells. The antibody expression level for the stable transfection of CHO-DG44 and HEK-293T cell cultures was determined by ELISA. The results of the experiments showed that the expression of FI6v3-IgA1 antibodies significantly increased when eukaryotic cells were transfected with the plasmid pBiPr-ABIgA1FI6-Iht in which the heavy chain of IgA1 contains introns and the promoters are arranged head-to-tail.

13 January 2022 in JID Innovations
Verified
Journal Article
Open access
CBCedric Badowski
Cedric Badowski
TTTong San Tan
Tong San Tan
TATeimur Aliev
Teimur Aliev
DTDavid Trudil
David Trudil
MLMaria Larina
Maria Larina
ELE. Birgitte Lane
E. Birgitte Lane
Epidermolysis bullosa is a group of severe skin blistering disorders, which currently have no cure. The pathology of epidermolysis bullosa is recognized as having an inflammatory component, but the role of inflammation in different epidermolysis bullosa disorders is unclear. Epidermolysis bullosa simplex (EBS) is primarily caused by sequence variants in keratin genes; its most severe form, EBS generalized severe, is characterized by aggregates of keratin proteins, and cell models of EBS generalized severe show constitutively elevated stress. IFN-γ is a major mediator of inflammation, and we show that the addition of IFN-γ alone to disease model keratinocytes promotes keratin aggregation, decreases cell–cell junctions, delays wound closure, and reduces cell proliferation. IFN-γ exposure weakens the intercellular cohesion of monolayers on mechanical stress, with IFN-γ–treated EBS monolayers more fragmented than IFN-γ–treated wild-type monolayers. A humanized monoclonal antibody to IFN-γ neutralized the detrimental effects on keratinocytes, restoring cell proliferation, increasing cell–cell adhesion, accelerating wound closure in the presence of IFN-γ, and reducing IFN-γ–mediated keratin aggregation in EBS cells. These suggest that treatment with IFN-γ blocking antibodies may constitute a promising new therapeutic strategy for patients with EBS and may also have ameliorating effects on other inflammatory skin diseases.

4 April 2022 in Biotechnology and Genetic Engineering Reviews
Verified
Journal Article
Closed access
VAVictoria Argentova
Victoria Argentova
TATeimur Aliev
Teimur Aliev
Dmitry DolgikhDmitry Dolgikh
Dmitry Dolgikh
ZPZuzana Pakanová
Zuzana Pakanová
JKJaroslav Katrlík
Jaroslav Katrlík
MKMikhail Kirpichnikov
Mikhail Kirpichnikov
Increasing the production of recombinant antibodies while ensuring high and stable protein quality remains a challenge in mammalian cell culture. This review is devoted to advances in the field of obtaining stable and optimal glycosylation of therapeutic antibodies based on IgA, as well as the subsequent issues of glycosylation control of glycoproteins during their production. Current studies also demonstrate a general need for a more fundamental understanding of the use of CHO cell-based producer cell lines, through which the glycoprofile of therapeutic IgA antibodies is produced and the dependence of glycosylation on culture conditions could be controlled. Optimization of glycosylation improves the therapeutic efficacy and can expand the possibilities for the creation of highly effective glycoprotein therapeutic drugs. Current status and trends in glycan analysis of therapeutic IgA, dominantly based on mass spectrometry and lectin microarrays are herein summarised as well.

1 November 2017 in Molecular Biology
Verified
Journal Article
Closed access
PDF file
VAV. V. Argentova
V. V. Argentova
TAT. K. Aliev
T. K. Aliev
VZV. V. Zarubaev
V. V. Zarubaev
SKSergei Klotchenko
Sergei Klotchenko
ASA. A. Shtro
A. A. Shtro
MKMikhail P. Kirpichnikov
Mikhail P. Kirpichnikov
Seasonal and highly infectious strains of the influenza A and influenza B viruses cause millions of cases of severe complications in elderly people, children, and patients with immune diseases each ye